
News|Articles|October 1, 2004
High-dose simvastatin fails to achieve primary end point in trial of ACS
Initiating high-dose simvastatin (Zocor, Merck) early after an acute coronary syndrome (ACS) event does not result in significantly superior clinical outcomes compared to delayed initiation of low-dose simvastatin.This major finding of phase Z of the A to Z Trial is in contrast to the results of 2 previous clinical trials in which aggressive therapy with atorvastatin (Lipitor, Pfizer) was found to be superior to less aggressive statin therapy in reducing the risk of adverse clinical events in ACS patients.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Drug Pricing Not Main Driver of State Medicaid Spending | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
PBM Reform Debate: Panelists Clash Over Spread Pricing and Rebates | AMCP Nexus 2025
4
Generalized Anxiety Disorder Affects More Than One in Ten U.S. Adults | AMCP Nexus 2025
5


















































